AAM Working To Mitigate Coronavirus Effects
US Association Says Contingency Planning Is A ‘Top Priority’
The US Association for Accessible Medicines says it is actively working with industry stakeholders to mitigate coronavirus-related disruptions to the off-patent industry’s supply chain, with contingency planning a “top priority.”
You may also be interested in...
India has published a list of APIs and formulations for which exports will be restricted, with immediate effect. The move comes against the backdrop of growing concerns over the off-patent industry’s supply chain given the ongoing pressures caused by the coronavirus outbreak.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.